Preparation and antitumor activity of bFGF-mediated active targeting doxorubicin microbubbles.
Characterization and antitumor activity of basic fibroblast growth factor-mediated active targeting doxorubicin microbubbles (bFGF-DOX-MB) were investigated. Pluronic F68 with chemical conjugation of doxorubicin (DOX-P) and peptide KRTGQYKLC-conjugated DSPE-PEG2000 were prepared. bFGF-DOX-MB had a normal distribution of particle size, with average particle size of 2.7 μm. Using A549 mouse model, bFGF-DOX-MB combined ultrasound showed the best inhibition effect on tumor volume growth among all the test groups. Similar conclusion was obtained from experimental measurements of tumor weight change and blood cell count. From the results, chemotherapeutic drug inhibition on tumor growth could be enhanced by local ultrasound combined with active targeting bFGF-DOX-MB, which might provide a potential application for ultrasound-mediated chemotherapy.
Department of Pharmacy, General Hospital of the Air Force , Beijing China.
Yan
Y
Wu
Cui-Tao
CT
Lu
Wen-Feng
WF
Li
Chang-Zheng
CZ
Sun
Wei
W
Yang
Yi
Y
Zhang
Zheng-Xing
ZX
Su
Yan
Y
Zhang
Hong-Xing
HX
Fu
Pin-Tong
PT
Huang
Hai-Feng
HF
Lv
Dan-Dan
DD
Dai
Xing
X
Li
Guang-Yong
GY
Lin
Song-Mei
SM
Luo
Ying-Zheng
YZ
Zhao
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D004339:Drug Compounding; D016503:Drug Delivery Systems / Q000009:adverse effects; D005240:Feasibility Studies; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D008819:Mice, Nude; D045423:Microbubbles / Q000009:adverse effects / Q000627:therapeutic use*; D009363:Neoplasm Proteins / Q000378:metabolism; D009842:Oligopeptides / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D054730:Protein Interaction Domains and Motifs; D011897:Random Allocation; D051497:Receptor, Fibroblast Growth Factor, Type 2 / Q000378:metabolism; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
D000903:Antibiotics, Antineoplastic; D009363:Neoplasm Proteins; D009842:Oligopeptides; D010446:Peptide Fragments; C588228:lysyl-arginyl-threonyl-glycyl-glutaminyl-tyrosyl-lysyl-leucyl-cysteine; D016222:Fibroblast Growth Factor 2; D004317:Doxorubicin; C496353:FGFR2 protein, human; D051497:Receptor, Fibroblast Growth Factor, Type 2